Patents by Inventor Peter Roller

Peter Roller has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • REDOX-STABLE, NON-PHOSPHORYLATED CYCLIC PEPTIDE INHIBITORS OF SH2 DOMAIN BINDING TO TARGET PROTEIN, CONJUGATES, THEREOF, COMPOSITIONS AND METHODS OF SYNTHESIS AND USE
    Publication number: 20080031812
    Abstract: A compound of formula: in which (i) aa1 is Adi and aa4 is Glu or (ii) each of aa1 and aa4 is Adi, L is sulfur, sulfoxide, oxygen or methylene, which compound (and its conjugates) bind to an SH2 domain in a protein comprising an SH2 domain, is non-phosphorylated, is redox-stable in vivo, is characterized by an IC50 in vivo of less than about 4.0 ?M with respect to the SH2 domain in Grb2, and, upon binding to the SH2 domain of Grb2, has a turn conformation. A conjugate comprising a compound as described above and a carrier agent, a composition comprising (i) a compound or a conjugate as described above and (ii) a carrier, a method of inhibiting binding of an SH2 domain in a protein comprising an SH2 domain to a target protein in an animal, wherein the SH2 domain is contacted with a target protein-binding inhibiting effective amount of a compound or a conjugate as described above, and a method of synthesizing such conjugates.
    Type: Application
    Filed: August 14, 2007
    Publication date: February 7, 2008
    Applicants: GOVERNMENT OF THE USA, REPRESENTED BY THE SECRETARY, DEPA., GEORGETOWN UNIVERSITY
    Inventors: Peter Roller, Ya-Qiu Long, Feng-Di T. Lung, C. Richter King, Dajun Yang, Johannes Voigt
  • Redox-stable, non-phosphorylated cyclic peptide inhibitors of SH2 domain binding to target protein, conjugates thereof, compositions and methods of synthesis and use
    Publication number: 20060014927
    Abstract: A compound of formula: in which (i) aa1 is Adi and aa4 is Glu or (ii) each of aa1 and aa4 is Adi, L is sulfur, sulfoxide, oxygen or methylene, which compound (and its conjugates) bind to an SH2 domain in a protein comprising an SH2 domain, is non-phosphorylated, is redox-stable in vivo, is characterized by an IC50 in vivo of less than about 4.0 ?M with respect to the SH2 domain in Grb2, and, upon binding to the SH2 domain of Grb2, has a turn conformation. A conjugate comprising a compound as described above and a carrier agent, a composition comprising (i) a compound or a conjugate as described above and (ii) a carrier, a method of inhibiting binding of an SH2 domain in a protein comprising an SH2 domain to a target protein in an animal, wherein the SH2 domain is contacted with a target protein-binding inhibiting effective amount of a compound or a conjugate as described above, and a method of synthesizing such conjugates.
    Type: Application
    Filed: September 13, 2005
    Publication date: January 19, 2006
    Applicants: Government of the U.S.A., represented by the Secretary, Dept. of Health and Human Services, Georgetown University
    Inventors: Peter Roller, Ya-Qiu Long, Feng-Di Lung, C. King, Dajun Yang
  • Serine protease inhibitors
    Publication number: 20050130883
    Abstract: The present disclosure concerns peptides and peptidomimetics having inhibitory activity against serine proteases. The disclosed peptides and peptidomimetics are particularly useful as selective inhibitors of matriptase and MTSP1. Pharmaceutical compositions comprising serine protease inhibitors and methods for administering the compositions also are disclosed.
    Type: Application
    Filed: September 30, 2004
    Publication date: June 16, 2005
    Inventors: Peter Roller, Peng Li